New Delhi, Oct. 8 -- Prices of anti-cancer drugs may fall by up to 70 per cent as the government is moving to cap trade margins at 30 per cent of the Maximum Retail Price (MRP) for non-scheduled anti-cancer medicines, according to official sources.

The proposed measure would cover branded and generic, domestic and imported, as well as patented and non-patented anti-cancer medicines, the sources said.

"In a major patient-centric intervention, the Government has decided to cap trade margins at 30 per cent of MRP for all non-scheduled anti-cancer drugs, covering branded and generic, domestic and imported, patented and non-patented medicines," official sources said.

The move is expected to cover expensive cancer drugs, including patented m...